Clinical trials: Covid19 Vaccine
COVID-19, Coronavirus Infections
Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) Phase III Clinical Trial
This clinical trial adopts a randomized, double-blind and placebo-controlled design. A total of 16000 participants are planned to be enrolled, of which, Cohort 1: 15000 participants vaccinated with ≥2 doses of inactivated…
- Trial name
- NCT05599516
- Testing
- LIBP-Rec-Vaccine, BIBP-Rec-Vaccine
- Where
- United Arab Emirates
- Volunteers
- 16,000 people, healthy volunteers welcome
- Sponsor
- National Vaccine and Serum Institute, China
COVID-19, Sars-CoV-2 Infection
Booster Vaccination Against COVID-19
A booster dose of vaccine (Turkovac or CoronaVac) will be administered to subjects who have passed at least 90 days and at most 270 days after the second dose of the first course of CoronaVac vaccine.
- Trial name
- NCT04979949
- Testing
- CoronaVac, Turkovac
- Where
- 4 sites in Turkey (Türkiye)
- Volunteers
- 222 people, healthy volunteers welcome
- Sponsor
- Health Institutes of Turkey
Influenza, COVID-19
Comparative Immunogenicity of Concomitant vs Sequential mRNA COVID-19 and Influenza Vaccinations
This is a prospective, randomized randomized immunologic study of response to influenza and SARS-CoV-2 vaccination across four of the US Influenza Vaccine Effectiveness (Flu VE) Network study sites.
- Trial name
- NCT06020118
- Testing
- Simultaneous Vaccination (Influenza Vaccine and mRNA COVID booster), Sequential Vaccination (Influenza vaccine then mRNA COVID booster), Sequential Vaccination (mRNA COVID booster then Influenza vaccine)
- Where
- 8 sites in United States
- Volunteers
- 455 people, healthy volunteers welcome
- Sponsor
- Duke University
Covid19
Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults and Boost (VXA-CoV2-1.1-S) at 1 Year Post Initial Vaccination in Subset of Subjects
VXA-CoV2-1 is a non-replicating Ad5 vector adjuvanted oral tableted vaccine being developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection.
- Trial name
- NCT04563702
- Testing
- VXA-CoV2-1
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Vaxart
COVID-19, Vaccination Hesitancy
An Online Game to Help Canadian Adults Identify COVID-19 Vaccine Misinformation With One-Month Follow-Up
COVID-19 vaccine misinformation contributed to vaccine hesitancy and preventable illness. This study tested whether a brief online game helps Canadian adults identify COVID-19 vaccine misinformation, and whether effects last one…
- Conditions
- COVID-19, Vaccination Hesitancy, Health Misinformation, Communication
- Trial name
- NCT07758296
- Testing
- Gamified misinformation refutation quiz, Refutational text blog post (active control)
- Where
- United States
- Volunteers
- 4,071 people, healthy volunteers welcome
- Sponsor
- University of South Carolina
Safety Issues
Safety Profile Following Inactivated COVID-19 Vaccine in Healthy Adults Aged >18 Years in Indonesia
The aim of this study is evaluating safety profile of COVID-19 Vaccine in healthy adults aged >18 years in Indonesia.
- Trial name
- NCT05037227
- Where
- Indonesia
- Volunteers
- 1,100 people, healthy volunteers welcome
- Sponsor
- PT Bio Farma
SARS-CoV-2
A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19
The mRNA-1273 vaccine is being developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection.
- Trial name
- NCT04470427
- Testing
- mRNA-1273
- Where
- 100 sites in United States
- Volunteers
- 30,415 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Herpes Zoster
A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine
The aim of this study was to evaluate the immune response and safety of both GlaxoSmithKline Biologicals SA's (GSK's) herpes zoster (HZ) subunit (su) vaccine in healthy adults 50 years of age (YOA) and older and quadrivalent…
- Trial name
- NCT05047770
- Testing
- HZ/su, Flu D-QIV, mRNA-1273
- Where
- 46 sites in United States
- Volunteers
- 2,013 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COVID-19 Lower Respiratory Infection
Phase I/II Study of COVID-19 DNA Vaccine (AG0302-COVID19 High-dose)
This study will assess the safety and immunogenicity of AG0302-COVID19 in healthy volunteers.
- Trial name
- NCT04993586
- Testing
- AG0302-COVID19 for Intramuscular Injection, AG0302-COVID19 for Intradermal Injection
- Where
- 6 sites in Japan
- Volunteers
- 422 people, healthy volunteers welcome
- Sponsor
- AnGes, Inc.
Covid-19 Vaccine
Serological Response to mRNA and Inactivated COVID-19 Vaccine in Health Care Workers in Hong Kong
Since the first local case of COVID-19 confirmed on 4 Feb 2020, Hong Kong has already experienced 4 waves of COVID-19 surge, with more than 9000 cases reported.
- Trial name
- NCT04898946
- Testing
- CoronaVac Vaccine, BNT162b2 Vaccine
- Where
- Hong Kong
- Volunteers
- 480 people
- Sponsor
- Hong Kong Sanatorium & Hospital
COVID-19
A Phase III Study of COVID-19 Vaccine EuCorVac-19 in Healthy Adults
This is a phase III, randomized, observer-blind, active-controlled, parallel group, multi-center study to compare the immunogenicity and safety of a preventive COVID-19 vaccine EuCorVac-19 to ChAdOx1 in healthy adults aged 18…
- Trial name
- NCT05572879
- Testing
- EuCorVac-19, ChAdOx1 nCoV-19
- Where
- Philippines
- Volunteers
- 2,600 people, healthy volunteers welcome
- Sponsor
- EuBiologics Co.,Ltd
Liver Disease Chronic
COVID-19 Vaccines in Patients With Chronic Liver Disease
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused pandemic since outbreak in 2020.Patients with chronic liver disease (CLD) are at higher risk of mortality and morbidity due to COVID-19.
- Trial name
- NCT05017805
- Testing
- COVID-19 Vaccines
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Beijing 302 Hospital
COVID-19, Vaccine Hesitancy
COVID-19 Vaccine Hesitancy Among Nurses
The purpose of this study is to investigate the correlation of intention to receive COVID-19 vaccine, recommendation behavior, and 5C psychological antecedents among Nurses.
- Conditions
- COVID-19, Vaccine Hesitancy, Vaccination, Nurses
- Trial name
- NCT05212974
- Testing
- Questionnaires
- Where
- Taiwan
- Volunteers
- 4,258 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
COVID-19, HIV Infections
Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in People With HIV Infected
Evaluation of immunogenicity and safety of the subjects infected with HIV to receive the schedule of two doses inactivated COVID-19 vaccine with the interval of 21 days .
- Trial name
- NCT05075070
- Testing
- Inactivated COVID-19 vaccine
- Where
- China
- Volunteers
- 400 people
- Sponsor
- China National Biotec Group Company Limited
COVID-19, SARS CoV 2 Infection
Neutralizing Power of Anti-SARS-CoV-2 (Anti-COVID-19) Serum Antibodies
Natural infection, vaccines and treatments (like monoclonal antibodies) lead to the appearance of a neutralizing power in the serum (due to induced or injected antibodies).
- Trial name
- PNAS (NCT05315583)
- Testing
- Collection of biological samples
- Where
- France
- Volunteers
- 9 people
- Sponsor
- Centre Hospitalier Régional d'Orléans
Coronavirus
Exploring Vaccine Confidence and Uptake of Potential COVID-19 Vaccines
The COVID-19 pandemic has highlighted deleterious US health inequities. Specifically, African Americans, Latinos, and Native Americans have and continue to shoulder a greater burden of COVID-19 infections and deaths in the US.
- Trial name
- NCT04731870
- Testing
- Survey research
- Where
- United States
- Volunteers
- 632 people, healthy volunteers welcome
- Sponsor
- East Carolina University
COVID-19
Impact of New Variants and Vaccines on the Course of COVID-19
Novel coronavirus disease (COVID-19), caused by Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, was first reported in December 2019 in Wuhan, China.
- Trial name
- COVID-19 (NCT05384886)
- Testing
- Polymerase chain reaction
- Where
- Turkey (Türkiye)
- Volunteers
- 15,967 people
- Sponsor
- Izmir Katip Celebi University
Evaluate Immune Responses Following mRNA COVID-19 Vaccine Administration Through Different Delivery Routes in Healthy Volunteers, SARS CoV-2
mRNA Covid-19 Vaccine Immune Response Comparisons Using Different Delivery Routes
The purpose of this study is to determine if immune responses differ when the mRNA COVID-19 vaccine is given through different delivery methods, including a needle-free injection system, or via intramuscular injection using…
- Trial name
- NCT06919796
- Testing
- COMIRNATY®
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- PharmaJet, Inc.
COVID-19, Respiratory Disease
Health Communication to Influence COVID-19 Vaccination Intent and Message Propagation
This is a randomised controlled experiment in the form of a web based survey study which randomly exposes participants to different forms of public health messages, after which participants will be assessed on their intent to…
- Conditions
- COVID-19, Respiratory Disease, Vaccine Refusal, Infectious Disease
- Trial name
- CONVINCE (NCT05244356)
- Testing
- Health message exposure
- Where
- Malaysia
- Volunteers
- 5,784 people, healthy volunteers welcome
- Sponsor
- Clinical Research Centre, Malaysia
COVID-19
COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial)
This phase 2 clinical trial will evaluate the safety and immunogenicity of additional doses of prototype and variant (alone or in combination) vaccine candidates in previously vaccinated participants with or without prior severe…
- Trial name
- NCT05289037
- Testing
- AS03, BNT162b2, BNT162b2 (B.1.1.529)
- Where
- 22 sites in United States
- Volunteers
- 1,270 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.